Dignitana Proudly Announces that the United States Patent and Trademark Office (USPTO) has Granted a Patent to Dignitana, Further Protecting the Company´s Scalp Cooling Technology Dignitana, a world leader in medical scalp cooling technology, has announced that it has been granted a patent by the USPTO. This patent has previously been granted in Europe, China, Korea and Japan, and now also in the United States with U.S. Patent number: 9,101,463. Dignitana has an active IP strategy and over the years worked to acquire rights in prioritized markets. Dignitana submitted the so-called PCT-application in 2008, and the decision by the USPTO provides Dignitana enhanced legal protection in the United States until 2031. This patent is part of Dignitana´s intellectual property (IP) portfolio, which consists of other patents, trademarks and industrial designs. The company’s portfolio provides a broad protection for its scalp cooling technology. Dignitana’s scalp cooling system, DigniCap®, consists of a tight-fitting silicone cooling cap connected to a cooling and control unit. Coolant circulates through tunnels in the cap. The temperature in the cooling cap is monitored and automatically regulated during the entire cooling treatment, through a patented technology of sensors in the cooling cap. The scope of protection of this new patent covers the specific shaping of labyrinth paths in the cooling cap. With this patent Dignitana has the right to exclude others from making, using, offering for sale, or selling the patented invention in, as well as importing into, the United States of America. To show to the market that Dignitana´s product is protected by this patent, the product or packaging will be marked with the patent number. Jan Richardsson, CEO Dignitana AB (publ): “Our scalp cooling system DigniCap®, for the reduction of chemotherapy related hair loss, is the only scalp-cooling device to have completed a formal trial for U.S. FDA approval. We are creating the necessary infrastructure for making DigniCap® widely available and accessible in the U.S. upon FDA Clearance. This legal protection is very important to have obtained at this point in time, as it gives us an additional competitive advantage in the U.S. market. To further strengthen our IP strategy we will, with a grant received from ALMI / Vinnova, conduct a review of our IP strategy for preserving and utilizing our patents, trademarks, and industrial designs in the best way, thereby obtaining and maintaining government protection and strengthening our brand power.” Media Contact: Caren Browning Jan Richardsson King Company Dignitana Chief Executive Officer 00 1 212 561 -7464 0046 46 16 30 92 Caren.Browning@kingcompr.com Jan.Richardsson@dignitana.se About Dignitana AB (publ) Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bankaktiebolag as Certified Advisor. For more information visit www.dignitana.com About the scalp cooling system DigniCap® Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.
Dignitana obtains patent in the United States of America
| Source: Dignitana AB
Attachments
